Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.

Papp, K A; Lebwohl, M G; Puig, L; Ohtsuki, M; Beissert, S; Zeng, J; Rubant, S; Sinvhal, R; Zhao, Y; Soliman, A M; Alperovich, G; Leonardi, C

Papp, K A; Lebwohl, M G; Puig, L; Ohtsuki, M; Beissert, S; Zeng, J; Rubant, S; Sinvhal, R; Zhao, Y; Soliman, A M; Alperovich, G; Leonardi, C.

Affiliation

Papp KA; K Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada.
Lebwohl MG; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Puig L; Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Ohtsuki M; Jichi Medical University, Tochigi, Japan.
Beissert S; Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Zeng J; AbbVie Inc., North Chicago, IL, USA.
Rubant S; AbbVie Inc., North Chicago, IL, USA.
Sinvhal R; AbbVie Inc., North Chicago, IL, USA.
Zhao Y; AbbVie Inc., North Chicago, IL, USA.
Soliman AM; AbbVie Inc., North Chicago, IL, USA.
Alperovich G; AbbVie Inc., Madrid, Spain.
Leonardi C; Central Dermatology, Richmond Heights, MO, USA.

Br J Dermatol ; 185(6): 1135-1145, 2021 12.

Article in En | MEDLINE | ID: mdl-34157132

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Quality of Life Type of study: Clinical_trials / Observational_studies / Prognostic_studies Aspects: Patient_preference Limits: Adult / Humans Language: En Journal: Br J Dermatol Year: 2021 Document type: Article Affiliation country: Canadá Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google